Caveolin-1, a stress-related oncotarget, in drug resistance

Zhiyu Wang; Neng Wang; Pengxi Liu; Fu Peng; Hailin Tang; Qianjun Chen; Rui Xu; Yan Dai; Yi Lin; Xiaoming Xie; Cheng Peng; Honglin Situ

doi:10.18632/oncotarget.5789

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Caveolin-1, a stress-related oncotarget, in drug resistance

Zhiyu Wang _, Neng Wang, Pengxi Liu, Fu Peng, Hailin Tang, Qianjun Chen, Rui Xu, Yan Dai, Yi Lin, Xiaoming Xie, Cheng Peng and Honglin Situ

PDF | HTML | How to cite

Oncotarget. 2015; 6:37135-37150. https://doi.org/10.18632/oncotarget.5789

Metrics: PDF 2934 views | HTML 4096 views | ?

Abstract

Zhiyu Wang1, Neng Wang2, Pengxi Liu1, Fu Peng3, Hailin Tang2, Qianjun Chen1, Rui Xu1, Yan Dai1, Yi Lin1, Xiaoming Xie2, Cheng Peng3 and Honglin Situ1

1 Department of Mammary Disease, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical Collage of Guangzhou University of Chinese Medicine, Guangzhou, China

2 Department of Breast Oncology, Sun Yat-sen Univeristy Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China

3 Pharmacy College, State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Guangzhou, China

Correspondence to:

Zhiyu Wang, email:

Keywords: Cav-1, cancer drug resistance, aerobic glycolysis, cancer stem cells, ABC transporters

Received: May 19, 2015 Accepted: September 08, 2015 Published: September 27, 2015

Abstract

Caveolin-1 (Cav-1) is both a tumor suppressor and an oncoprotein. Cav-1 overexpression was frequently confirmed in advanced cancer stages and positively associated with ABC transporters, cancer stem cell populations, aerobic glycolysis activity and autophagy. Cav-1 was tied to various stresses including radiotherapy, fluid shear and oxidative stresses and ultraviolet exposure, and interacted with stress signals such as AMP-activated protein kinase. Finally, a Cav-1 fluctuation model during cancer development is provided and Cav-1 is suggested to be a stress signal and cytoprotective. Loss of Cav-1 may increase susceptibility to oncogenic events. However, research to explore the underlying molecular network between Cav-1 and stress signals is warranted.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5789

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Caveolin-1, a stress-related oncotarget, in drug resistance

Abstract